But Strong Legislation Unlikely Given Patient and Industry Opposition
HHS has proposed regulations to attack high drug prices, a priority for the current administration. Both parties have spoken out against the drug companies but the change in control of the House is no guarantee of pricing legislation moving forward. And if drug manufacturers, PBMs, and others are adamant about tackling drug prices, why do they oppose the best cost-cutting proposals?
The authors evaluate the impact of a comprehensive therapeutic interchange program (CTIP) in hospitalized patients with COPD and demonstrate that using a pharmacist-led CTIP of COPD inhalers does not worsen patient outcomes and may provide pharmacy cost savings.
The authors review what is necessary for interpreting culture results: timing of cultures, common culture sites, rapid diagnostic tests, and more. Rapid diagnostic tests and conventional susceptibility testing can be used to select the most appropriate antibiotic.
From IHS, we report on complementary and alternative medicine use by patients and practitioners, the effects of biological hemp-derived cannabidiol on PTSD in military veterans, and more.
The current rebate “safe harbor” encourages drug manufacturers to inflate list prices. The HHS’s newly proposed rule threatens to eliminate this safe harbor but offers two new ones instead.
The familiar but ambiguous sigs on prescriptions are often of limited help to patients and pharmacists. Sometimes, the instruction to “use as directed” has resulted in serious errors.
Motegrity (prucalopride) for chronic idiopathic constipation; Aemcolo (rifamycin) for travelers’ diarrhea; and Dextenza (dexamethasone ophthalmic insert) for ocular pain after ophthalmic surgery
